文献速递胃肠外科围术期管理与 ERAS

Roux-en-Y胃旁路术后边缘性溃疡:发生、复发及再手术的危险因素

Marginal ulceration following Roux-en-Y gastric bypass: risk factors for ulcer development, recurrence and need for revisional surgery.
PubMed 文献 · Surg Endosc · 2020-05-18

该研究纳入2011至2017年2830例Roux-en-Y胃旁路术患者,边缘性溃疡发生率为6.9%,1%因顽固性溃疡需再手术。吸烟史(HR 5.03)、免疫抑制(HR 4.60)和术前使用非甾体抗炎药(HR 3.11)显著增加需再手术的边缘性溃疡风险。再手术患者症状缓解率仅36%,57%出现复发性溃疡。

要点

  • 边缘性溃疡发生率为6.9%,1%需再手术。
  • 吸烟史、免疫抑制、术前NSAID使用增加再手术风险。
  • 再手术后症状缓解率低(36%),复发率高(57%)。

核心结论

  • 有吸烟史和使用免疫抑制药物的患者发生药物治疗失败的边缘性溃疡风险显著更高。

研究设计与样本

  • 回顾性队列研究,纳入2011至2017年单中心2830例Roux-en-Y胃旁路术患者,数据来自代谢与减重手术认证与质量改进项目及安大略减重登记处。

主要发现

  • 边缘性溃疡发生率为6.9%,1%的患者因顽固性溃疡需再手术。
  • 有吸烟史的患者需再手术的边缘性溃疡风险显著增加(HR 5.03)。
  • 免疫抑制患者需再手术的边缘性溃疡风险显著增加(HR 4.60)。
  • 术前使用NSAID的患者需再手术的边缘性溃疡风险显著增加(HR 3.11)。
  • 再手术患者中仅36%症状缓解,57%出现复发性溃疡。

临床怎么用

  • 对拟行Roux-en-Y胃旁路术的患者,应评估吸烟史、免疫抑制状态和术前NSAID使用情况以识别高危人群。

局限性

  • 需要更多证据来指导减重手术患者的围术期管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Marginal ulcer formation is a known complication following RYGB. While most respond to medical therapy, many patients have recurrent or chronic MU. Although non-steroidal anti-inflammatory drug (NSAID) use, smoking and Helicobacter pylori infection are known risk factors of MU, little is known about what increases the likelihood of developing recalcitrant ulcers. The objective of this study is to identify risk factors for marginal ulcer (MU) formation, including recalcitrant ulcers requiring surgical revision, and to define the incidence and outcomes of revisional surgery. METHODS: All patients who underwent RYGB between 2011 and 2017 at a high-volume academic center were included. Patients with a postoperative diagnosis of MU were identified from the institution's bariatric database. Patient characteristics, operative data and surgical outcomes were analyzed using data collected in the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program and the Ontario Bariatric Registry. RESULTS: A total of 2830 RYGB were performed during the study period. The incidence of MU was 6.9% with 1% of patients requiring revisional surgery for a recalcitrant ulcer. Patients with a history of smoking (HR 5.03), immunosuppression (HR 4.60) and preoperative NSAID use (HR 3.11) were significantly more likely to develop a MU requiring surgical revision. Patients undergoing revision reported resolution of their symptoms in only 36% of cases with 57% developing a recurrent ulcer. CONCLUSION: Patients with a history of smoking and use of immunosuppressive medication were at significantly higher risk of developing MU that failed medical therapy. Additional evidence is needed to inform perioperative management of bariatric patients.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Di Palma A, Liu B, Maeda A, et al. Marginal ulceration following Roux-en-Y gastric bypass: risk factors for ulcer development, recurrence and need for revisional surgery. Surg Endosc. 2020. PMID: 32424625. doi:10.1007/s00464-020-07650-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。